Hautaerzte Zentrum Hannover GbR
- Address
- lock Available on a paid plan
Hautaerzte Zentrum Hannover GbR - Dermatological Research Center
Hautaerzte Zentrum Hannover GbR is a specialized dermatological research center with focused expertise in complex inflammatory skin conditions. The center demonstrates particular strength in conducting advanced clinical trials for chronic and difficult-to-treat dermatological diseases, contributing to the development of novel therapeutic approaches.
- Long-term safety and efficacy evaluation of biologic therapies in severe dermatological conditions
- Hidradenitis suppurativa treatment research and innovative therapeutic interventions
- Advanced immunomodulatory therapies including novel monoclonal antibodies
The research center specializes in extension studies that assess the long-term safety and tolerability of emerging treatments for moderate to severe hidradenitis suppurativa. Their clinical trial portfolio includes investigating cutting-edge biologic agents such as bimekizumab and sonelokimab, focusing on their sustained efficacy and safety profiles in patients with chronic inflammatory skin diseases. This work is essential for establishing the viability of these therapies for extended clinical use in challenging dermatological conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Incyte Corp.2trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hautaerzte Zentrum Hannover GbR
lock Showing 1 of 7 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | Incyte Corp. | Phase III | Not Recruiting | Jun 2023 | Dec 2025 |
IMP list
lock Showing 1 of 5 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| 4-[3-(Cyanomethyl)-3-(3',5'-Dimethyl-1H,1'H-[4,4'-Bipyrazol]-1-Yl)Azetidin-1-Yl]-2,5-Difluoro-N-[(2S)-1,1,1-Trifluoropropan-2-Yl]Benzamide | 2 | Unknown | 2023-06-15 | 2024-07-26 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.